Somatropin recombinant API Manufacturers

Looking for Somatropin recombinant API 12629-01-5?

Description:

Here you will find a list of producers, manufacturers and traders of Somatropin recombinant. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Somatropin recombinant 

Synonyms:

GH , GH-N , Growth hormone , Pituitary growth hormone , Somatotropin precursor , Somatropin , Somatropin [rDNA origin] , HGH , Human growth hormone , Recombinant HGH  

Cas Number:

12629-01-5 

DrugBank number:

DB00052 

Unique Ingredient Identifier:

NQX9KB6PCL

Somatropin recombinant is a type of Somatropin Agonists

Somatropin agonists are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that are designed to mimic the action of the natural human growth hormone, somatropin. These agonists are developed to interact with specific receptors in the body, promoting growth and development.

Somatropin agonists have gained significant attention in the pharmaceutical industry due to their potential applications in various medical conditions. They are primarily used in the treatment of growth disorders, such as growth hormone deficiency in children and adults. By binding to the somatropin receptor, these agonists stimulate the production of insulin-like growth factor-1 (IGF-1), which is responsible for promoting tissue growth and development.

One of the advantages of somatropin agonists is their enhanced stability and bioavailability compared to naturally occurring somatropin. This allows for better control of dosage and consistent therapeutic effects. Furthermore, these agonists can be administered through various routes, including subcutaneous injection, making them convenient for patients.

The development of somatropin agonists involves rigorous research and optimization to ensure their safety and efficacy. Pharmaceutical companies employ advanced techniques, such as recombinant DNA technology, to produce these synthetic analogs. Quality control measures are implemented throughout the manufacturing process to ensure batch-to-batch consistency and adherence to regulatory standards.

In conclusion, somatropin agonists are a valuable subcategory of pharmaceutical APIs used in the treatment of growth disorders. Their ability to mimic the action of somatropin and promote tissue growth makes them a promising therapeutic option for patients in need. Ongoing research and development in this field aim to further enhance the efficacy and safety of somatropin agonists, providing improved treatment options for individuals with growth-related conditions.

Somatropin recombinant (Somatropin Agonists), classified under Hormonal Agents

Hormonal agents are a prominent category of pharmaceutical active pharmaceutical ingredients (APIs) widely used in the medical field. These substances play a crucial role in regulating and modulating hormonal functions within the body. Hormonal agents are designed to mimic or manipulate the effects of naturally occurring hormones, allowing healthcare professionals to treat various endocrine disorders and hormonal imbalances.

Hormonal agents are commonly employed in the treatment of conditions such as hypothyroidism, hyperthyroidism, diabetes, and hormonal cancers. These APIs work by interacting with specific hormone receptors, either by stimulating or inhibiting their activity, to restore the balance of hormones in the body. They can be administered orally, intravenously, or through other routes depending on the specific medication and patient needs.

Pharmaceutical companies employ rigorous manufacturing processes and quality control measures to ensure the purity, potency, and safety of hormonal agent APIs. These APIs are synthesized using chemical or biotechnological methods, often starting from natural hormone sources or through recombinant DNA technology. Stringent regulatory guidelines are in place to guarantee the efficacy and safety of hormonal agent APIs, ensuring that patients receive high-quality medications.

As the demand for hormone-related therapies continues to grow, ongoing research and development efforts focus on enhancing the effectiveness and reducing the side effects of hormonal agent APIs. This includes the exploration of novel delivery systems, advanced formulations, and targeted drug delivery methods. By continuously advancing our understanding and capabilities in hormonal agents, the medical community can improve patient outcomes and quality of life for individuals with hormonal disorders.